December 8, 2017 08:57 AM ESTUpdated 10:29 AM
Peer Review

Cyn­thia Collins ex­its Hu­man Longevi­ty; Sec­tion 32 wel­comes Michael Pelli­ni; Sil­ver­back beefs up its C-suite

Amber Tong

→ Michael Pelli­ni has just jumped in­to a se­nior role at one of the most in­trigu­ing new ven­ture funds in the bio­phar­ma/health­care world …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Bris­tol My­ers re­veals more job cuts in New Jer­sey

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta 

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Gilead buys ex­per­i­men­tal HIV vac­cines from a small Barcelona biotech

A service from the Financial Times